Adam Fine is the Co-Founder, General Partner, and CEO of Windham Venture Partners. See sector focus and contact routes.
Adam Fine is the Co-Founder, General Partner, and CEO of Windham Venture Partners, a New York-based venture capital firm he established in 2006 with nearly two decades of prior experience in healthcare investing and medical technology[1][3][7]. His investment thesis targets early-stage healthcare companies, specifically focusing on Seed and Series A rounds in the medical technology and digital health sectors[3][9]. The firm typically writes checks between $1 million and $5 million, with Adam Fine often serving as the lead partner on deals, having led 19 transactions to date[1][9]. Notable portfolio companies in his network include NeuSpera Medical, Personal Genome Diagnostics, Cureatr, and Cartiva, reflecting the firm’s focus on category-defining health products[5]. Fine brings deep operational expertise from his previous roles as Vice President and General Manager at I-many and in business development at Cordis and Biosense, where he worked closely with Johnson & Johnson’s venture arm[1][3]. While specific public writing is not detailed in the available sources, his distinctive point of view centers on backing visionary leaders at the intersection of medical technology and digital
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Adam Fine · Full investor directory · Investor access · Company funding database